Clinical Studies of
Niraparib
The drug was
evaluated in clinical studies involving 553 people with any of these recurring
cancers who had had their tumors shrunk by at least two doses of platinum-based
chemotherapy. The average progression-free survival of certain women given
Niraparib was 21 months, compared with 5.5 months among women who took a
placebo, the FDA said.
No comments:
Post a Comment